Clover Health Investments Corp (CLOV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.66B
Last updated: Nov 17, 2026 at 11:05 AM ET
Clover Health Investments Corp (CLOV) Earnings: Report Dates and Results
Clover Health Investments (CLOV) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Clover Health Investments reported EPS of $0.01, above the -$0.01 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CLOV has an expected report date of Feb 24, 2027.
CLOV Earnings Call
The latest CLOV earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 25 quarters below that had an estimate, CLOV beat 15, missed 7 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $759.30M, up 52.9% from $496.65M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.01 | -$0.01 | N/A | +200.00% | Beat | N/A | 1 | 0 up, 1 down | Nov 4, 2026 | $759.30M |
| Jun 30, 2026 | $0.06 | $0.05 | $0.05 - $0.05 | +20.00% | Beat | +100.0% | 1 | N/A | Aug 5, 2026 | $743.17M |
| Mar 31, 2026 | $0.07 | $0.07 | $0.07 - $0.07 | 0.00% | In line | +40.0% | 1 | 0 up, 1 down | May 6, 2026 | $749.19M |
| Dec 31, 2025 | -$0.10 | -$0.11 | N/A | +9.09% | Beat | N/A | 1 | 0 up, 1 down | Feb 26, 2026 | $487.71M |
| Sep 30, 2025 | -$0.05 | $0.02 | $0.02 - $0.02 | -350.00% | Miss | N/A | 1 | 1 up, 0 down | Nov 4, 2025 | $496.65M |
| Jun 30, 2025 | $0.03 | $0.03 | $0.03 - $0.03 | 0.00% | In line | +50.0% | 1 | 1 up, 0 down | Aug 5, 2025 | $477.62M |
| Mar 31, 2025 | $0.05 | -$0.07 | -$0.07 - -$0.07 | +171.43% | Beat | N/A | 1 | 0 up, 1 down | May 6, 2025 | $462.33M |
| Dec 31, 2024 | -$0.05 | -$0.07 | -$0.07 - -$0.06 | +23.08% | Beat | N/A | 2 | 0 up, 1 down | Feb 27, 2025 | $336.50M |
| Sep 30, 2024 | -$0.02 | -$0.03 | -$0.05 - -$0.03 | +33.33% | Beat | N/A | 3 | 0 up, 0 down | Nov 6, 2024 | $330.99M |
| Jun 30, 2024 | $0.02 | -$0.04 | -$0.06 - -$0.04 | +150.00% | Beat | N/A | 3 | 0 up, 0 down | Aug 5, 2024 | $356.26M |
| Mar 31, 2024 | -$0.05 | -$0.08 | -$0.09 - -$0.06 | +37.50% | Beat | N/A | 3 | 0 up, 0 down | May 7, 2024 | $346.92M |
| Dec 31, 2023 | -$0.14 | -$0.14 | -$0.18 - -$0.10 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Mar 12, 2024 | $307.66M |
| Sep 30, 2023 | -$0.08 | -$0.11 | -$0.13 - -$0.09 | +27.27% | Beat | N/A | 3 | 0 up, 0 down | Nov 6, 2023 | $306.03M |
| Jun 30, 2023 | -$0.05 | -$0.13 | -$0.20 - -$0.10 | +61.54% | Beat | N/A | 5 | 0 up, 0 down | Aug 8, 2023 | $320.14M |
| Mar 31, 2023 | -$0.14 | -$0.17 | -$0.23 - -$0.12 | +17.65% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2023 | $321.99M |
| Dec 31, 2022 | -$0.17 | -$0.26 | -$0.36 - -$0.16 | +34.62% | Beat | N/A | 5 | 0 up, 0 down | Feb 28, 2023 | N/A |
| Sep 30, 2022 | -$0.16 | -$0.24 | -$0.36 - -$0.15 | +33.33% | Beat | N/A | 5 | 0 up, 0 down | Nov 7, 2022 | $855.43M |
| Jun 30, 2022 | -$0.22 | -$0.20 | -$0.27 - -$0.15 | -10.00% | Miss | N/A | 5 | 0 up, 0 down | Aug 8, 2022 | $845.08M |
| Mar 31, 2022 | -$0.16 | -$0.27 | -$0.36 - -$0.16 | +40.74% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2022 | $886.37M |
| Dec 31, 2021 | -$0.28 | -$0.26 | -$0.37 - -$0.15 | -7.69% | Miss | N/A | 6 | N/A | Feb 28, 2022 | $431.63M |
| Sep 30, 2021 | -$0.08 | -$0.23 | -$0.35 - -$0.12 | +65.22% | Beat | -126.8% | 4 | N/A | Nov 9, 2021 | $426.76M |
| Jun 30, 2021 | -$0.78 | -$0.14 | -$0.20 - -$0.07 | -457.14% | Miss | -362.8% | 3 | N/A | Aug 11, 2021 | $411.26M |
| Mar 31, 2021 | -$0.13 | -$0.10 | -$0.12 - -$0.09 | -30.00% | Miss | N/A | 3 | N/A | May 17, 2021 | $199.15M |
| Dec 31, 2020 | -$1.90 | -$0.84 | N/A | -126.19% | Miss | N/A | N/A | N/A | Jan 12, 2021 | $162.08M |
| Sep 30, 2020 | $0.30 | $0.30 | N/A | -0.37% | Miss | N/A | N/A | N/A | Dec 2, 2020 | $227.88M |
| Jun 30, 2020 | $0.30 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2020 | $168.77M |
| Mar 31, 2020 | -$0.27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 4, 2020 | $171.92M |
| Dec 31, 2019 | -$0.27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | N/A |
| Jun 30, 2019 | -$1.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $117.91M |
| Mar 31, 2019 | -$2.76 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2019 | $117.91M |
| Dec 31, 2018 | -$2.76 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.07, after -$0.10 the year before. It was -$2.76 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.07 | N/A |
| Dec 31, 2024 | -$0.10 | N/A |
| Dec 31, 2023 | -$0.41 | N/A |
| Dec 31, 2022 | -$0.71 | N/A |
| Dec 31, 2021 | -$1.27 | N/A |
| Dec 31, 2020 | -$1.57 | N/A |
| Dec 31, 2019 | -$4.23 | N/A |
| Dec 31, 2018 | -$2.76 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,200 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,194 | 9 | |
| 2026Q2 | Jun 30, 2026 | 4,821 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,138 | 6 | |
| 2025Q4 | Dec 31, 2025 | 4,824 | 6 | |
| 2025Q3 | Sep 30, 2025 | 4,699 | 5 | |
| 2025Q2 | Jun 30, 2025 | 4,590 | 7 | |
| 2025Q1 | Mar 31, 2025 | 4,628 | 7 | |
| 2024Q4 | Dec 31, 2024 | 4,565 | 6 |
2026Q3 Earnings Call
Opening remarks
Ryan Schmidt Investor Relations Good afternoon, everyone. Joining me on our call today to discuss the company's third quarter 2026 results are Andrew Toy, Clover Health's Chief Executive Officer; and Clay Thornton, the company's Chief Financial Officer. You can find today's press release and the accompanying supplemental slides as well as the company's most recent investor deck in the Investor Events and Presentations section of our website at investors.cloverhealth.com. This webcast is being recorded, and a replay will be available in the Investor Relations section of the Clover Health website. I'd also like to caution you that we may make forward-looking statements during today's call that are subject to risks and uncertainties, including expectations about future performance. Factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the Risk Factors section of our most recent annual report on Form 10-K and other SEC filings. Information about non-GAAP financial measures referenced, including a reconciliation of those measures to GAAP measures, can be found in the earnings materials available on our website. With that, I'll now turn the call over to Andrew.
Andrew Toy CEO Thank you, Ryan, and welcome, everyone, to our third quarter earnings call. There is a lot to be excited about at Clover right now. We expect to deliver our first full year of GAAP net income profitability this year. Our flagship PPO continues to rank #1 in the country on core HEDIS measures. Early AEP results are reinforcing the strength of our 2027 plan designs, and there is a meaningful 2027 earnings opportunity within our growing base of returning members. All of this is built on a very strong 2026 foundation. Through the first 9 months, we've grown membership by nearly 50% year-over-year, increased consolidated gross profit by over $160 million, more than doubled adjusted EBITDA to $97 million, and improved GAAP net income by nearly $100 million, which we believe positions us to be GAAP profitable on a full-year basis in 2026, an important milestone for our business. What's most important to me is what is driving our results. At Clover, we bring our health plan, clinically focused AI technology, and financial approach together in one model. Clover Assistant improves care across a broad physician network. Our full-risk structure lets us retain the entire upside value as members stay and cohorts mature. And our focused growth strategy lets us scale with discipline. We believe that is why our model is working today and getting stronger as we grow. Now let's shift to discussing Stars. We are incredibly proud that our flagship PPO plan achieved 5 Stars for payment year 2028, making it the largest 5-Star PPO contract in the country.
Frequently Asked Questions About CLOV
When is Clover Health Investments's next earnings date?
Clover Health Investments's next earnings report is expected for Feb 24, 2027.
Did CLOV beat earnings estimates last quarter?
Yes. Clover Health Investments reported EPS of $0.01 for the quarter ended Sep 30, 2026, above the -$0.01 estimate, a 200.00% surprise.
What EPS do analysts expect from CLOV next quarter?
The consensus EPS estimate for Clover Health Investments for the quarter ending Dec 31, 2026 is -$0.05 from 7 analysts, with estimates from -$0.05 to -$0.05.
How often does CLOV beat earnings estimates?
Clover Health Investments beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +9.20%.
CLOV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors